Skip to main content
. 2021 Feb 4;106(5):1345–1351. doi: 10.1210/clinem/dgab065

Figure 2.

Figure 2.

Analysis of serious renal events, serious gastrointestinal (GI) events, and serious cardiac conduction disorders. aPatients age 65 years or older: dulaglutide, 2619; placebo, 2637; and patients younger than 65 years: dulaglutide, 2330; placebo, 2315. bSupraventricular tachycardia or cardiovascular (CV) conduction disorders. HR, hazard ratio.